Search Results
Jun 03, 2026, 07:00 ET Full Circle Lithium Successfully Extinguishes Persistent C&D Landfill Lithium-Ion Battery Fire
https://www.epa.gov/landfills/industrial-and-construction-and-demolition-cd-landfills About Full Circle Lithium Corp.FCL is a U.S.-based
More news about: Full Circle Lithium Inc
Jun 03, 2026, 00:00 ET Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102
More news about: Antengene Corporation Limited
Jun 02, 2026, 10:02 ET Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody (Xd).SELECT IMPORTANT SAFETY INFORMATIONWarnings and PrecautionsThrombocytopenia:
More news about: Karyopharm Therapeutics Inc.
Jun 02, 2026, 10:00 ET Sony Electronics Bringing New Technologies Including Marquee Display Solutions and Powerful PTZ Cameras to InfoComm 2026
Crystal LED S Series, a mid‑market dvLED display line that delivers 800 cd/m² brightness, accurate color, ease of deployment, and low reflection. The two S Series models are slim, scalable, and energy‑efficient, while offering
More news about: Sony Electronics, Inc.
Jun 02, 2026, 09:31 ET AvenCell Therapeutics to Report Phase 1a Results of First-in-Class Switchable Allogeneic CD123 CAR-T Therapy for AML in Late-Breaking oral presentation at EHA 2026
completed Phase 1a portion of the RevSTAR-123 study, evaluating AvenCell's investigational switchable allogeneic CAR-T candidate (AVC-201) in patients with CD123-positive relapsed/refractory (r/r) or minimal residual disease (MRD) positive acute myeloid leukemia (AML), will be presented in a late-breaking oral
More news about: AvenCell Therapeutics, Inc.
Jun 02, 2026, 09:02 ET A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
dose-escalation basket trial joins ongoing work on GTB-3650, the company's second TriKE candidate, which has been enrolling patients with relapsed or refractory CD33-expressing blood cancers, including refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, in a design that steps through cohorts
More news about: USA News Group
Jun 02, 2026, 08:59 ET Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody (Xd).SELECT IMPORTANT SAFETY INFORMATIONWarnings and PrecautionsThrombocytopenia:
More news about: Karyopharm Therapeutics Inc.
Jun 02, 2026, 07:00 ET Tech Mahindra and StackGen Announce Partnership to Power Agentic AI for Enterprise Cloud
gain AI-powered automation across infrastructure, pipelines, SRE, and observability — accelerating cloud transformation without disrupting existing CI/CD investments or DevOps toolchains.Tech Mahindra has been at the forefront of enabling large-scale enterprise transformation programs for global
More news about: StackGen
Jun 02, 2026, 07:00 ET Tech Mahindra and StackGen Announce Partnership to Power Agentic AI for Enterprise Cloud
gain AI-powered automation across infrastructure, pipelines, SRE, and observability — accelerating cloud transformation without disrupting existing CI/CD investments or DevOps toolchains.Tech Mahindra has been at the forefront of enabling large-scale enterprise transformation programs for global
More news about: StackGen
Jun 01, 2026, 21:30 ET MSI Showcases Liquid-Cooled AI Infrastructure, NVIDIA MGX, NVIDIA DGX Station and DC-MHS Platforms at COMPUTEX 2026
distribution.CD281-S4051-X4 (Liquid Cooling): A liquid-cooled 2OU 4-Node platform supporting a single AMD EPYC 9005 processor, 12 DDR5 DIMMs, and 4 E1.S NVMe bays per node for AI inference and cloud-native infrastructure.CD281-S4051-X2: A 2OU 2-Node platform supporting a
More news about: MSI
Jun 01, 2026, 21:30 ET MSI presenteert vloeistofgekoelde AI-infrastructuur, NVIDIA MGX, NVIDIA DGX Station en DC-MHS-platformen op COMPUTEX 2026
48Vdc-verzamelrail.CD281-S4051-X4 (vloeistofkoeling): een vloeistofgekoeld 2OU 4-node-platform dat een enkele AMD EPYC 9005-processor, 12 DDR5 DIMM's en 4 E1.S NVMe-bays per node ondersteunt voor AI-inferentie en cloud-native infrastructuur.CD281-S4051-X2: een OU 2-node-platform dat
More news about: MSI
Jun 01, 2026, 21:30 ET MSI Showcases Liquid-Cooled AI Infrastructure, NVIDIA MGX, NVIDIA DGX Station and DC-MHS Platforms at COMPUTEX 2026
distribution.CD281-S4051-X4 (Liquid Cooling): A liquid-cooled 2OU 4-Node platform supporting a single AMD EPYC 9005 processor, 12 DDR5 DIMMs, and 4 E1.S NVMe bays per node for AI inference and cloud-native infrastructure.CD281-S4051-X2: A 2OU 2-Node platform supporting a
More news about: MSI
Jun 01, 2026, 21:30 ET MSI präsentiert auf der COMPUTEX 2026 flüssigkeitsgekühlte KI-Infrastruktur sowie die Plattformen NVIDIA MGX, NVIDIA DGX Station und DC-MHS
CD281-S4051-X4 (Flüssigkeitskühlung): Eine flüssigkeitsgekühlte 2OU-Plattform mit 4 Knoten, die einen einzelnen AMD EPYC 9005-Prozessor, 12 DDR5-DIMMs und 4 E1.S-NVMe-Einschübe pro Knoten für KI-Inferenz und cloudnative Infrastruktur unterstützt.CD281-S4051-X2: Eine 2OU-Plattform
More news about: MSI
Jun 01, 2026, 21:30 ET MSI présente l'infrastructure IA à refroidissement liquide, les plateformes NVIDIA MGX, NVIDIA DGX Station et DC-MHS au COMPUTEX 2026.
continu.CD281-S4051-X4 (à refroidissement par liquide) : Une plateforme 2OU 4 nœuds à refroidissement par liquide prenant en charge un seul processeur AMD EPYC 9005, 12 DIMM DDR5 et 4 baies NVMe E1.S par nœud pour l'inférence IA et l'infrastructure cloud-native.CD281-S4051-X2 : plateforme
More news about: MSI
Jun 01, 2026, 16:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
arlatamab) IMDYLLTRA is a first-in-class targeted immunotherapy engineered by Amgen researchers to bind to both DLL3 on tumor cells and CD3 on T cells, thereby activating T cells to kill DLL3-expressing SCLC cells. This results in the formation of a cytolytic synapse with lysis of the cancer
More news about: Amgen
Jun 01, 2026, 08:00 ET Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
the clinical strategy and execution of the company's lead hematology and oncology programs, including monoclonal antibody therapeutics targeting CD19, CD38, and PSMA. He began his pharmaceutical career at Merck KGaA, where over nearly a decade, he led global clinical development and life cycle management
More news about: Actinium Pharmaceuticals, Inc.
Jun 01, 2026, 08:00 ET Salt Security launches Salt Code, the first agentic security solution to enforce security policies inside AI coding assistants
works with any MCP-compatible assistant or code review workflow.Govern in the pipeline. Policy validation extends into CI/CD workflows. Violations are blocked before they reach production. Downstream SAST and DAST findings drop dramatically because the underlying issues were
More news about: Salt Security
Jun 01, 2026, 07:00 ET Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration
first-in-class asset targeting CD28 shedding, a novel immune evasion mechanism with the potential to redefine T-cell modulation in cancer. Given the central role of CD28 in T-cell activation, BND-67 introduces a fundamentally new approach to restoring immune responsiveness. By preserving CD28 signaling, it enhances
More news about: Biond Biologics Ltd.; GIBF
Jun 01, 2026, 03:13 ET Share buybacks in Ericsson during the period May 25 - May 29, 2026
https://mb.cision.com/Public/15448/4355544/b8458352e4446cd5.xlsxDaily Ericsson Share
More news about: Ericsson
Jun 01, 2026, 03:10 ET Share buybacks in Ericsson during the period May 25 - May 29, 2026
https://mb.cision.com/Public/15448/4355544/b8458352e4446cd5.xlsxDaily Ericsson
More news about: Ericsson
May 31, 2026, 20:15 ET ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
dose-dependent upregulation of Ki67 (proliferation due to PD-1 and CTLA-4 blockade) and ICOS (activation due to CTLA-4 blockade) expression on both CD4+ and CD8+ T cells, collectively demonstrating effective PD-1 and CTLA-4 inhibition by CS2009.Serum-free VEGFA reduced deeply and rapidly across
More news about: CStone Pharmaceuticals
May 31, 2026, 16:12 ET 華住集團於《2025可持續發展報告》中展示 ESG 進展
200 萬元人民幣，以支持香港的消防救援及重建工作。《2025 年可持續發展報告》全文已上載至華住的投資者關係網站：https://ir.hworld.com/static-files/0e03b62c-199a-47a7-be92-6ad39c7a3cd1關於華住集團有限公司華住集團有限公司 (NASDAQ:
More news about: H World Group
May 30, 2026, 15:25 ET Menarini Group 於 2026 年美國臨床腫瘤學會 (ASCO) 週年大會上發表第 1b/2 期 ELEVATE 研究中，使用埃拉司群 (Elacestrant) 聯合卡帕塞替尼 (Capivasertib) 治療 ER+、HER2- 轉移性乳癌 (mBC) 患者的最新數據。
(ER) 陽性、第 2 型人類表皮生長因子受體 (HER2) 陰性、ESR1 突變的晚期或轉移性乳癌，並且在至少接受過一線內分泌治療後病情仍出現惡化的停經後女性或成年男性患者。 Stemline 亦在美國、歐洲及其他全球地區銷售他格索芙 (tagraxofusp-erzs)。這是一種針對 CD123 的新型標靶藥物，用於治療母細胞性漿細胞樣樹突細胞腫瘤 (BPDCN) 患者，即侵襲性血液癌症。 此外，Stemline 在歐洲銷售塞利尼索 (selinexor)，這是一種用於治療多發性骨髓瘤的 XPO1 (出口蛋白 1) 抑制劑。 該公司亦分別針對乳癌及血液惡性腫瘤適應症，進行多項有關埃拉司群和他格索芙的適應症擴展研究，並且擁有龐大的臨床研發管線，當中包括多種處於不同開發階段、針對多種實體腫瘤和血液惡性腫瘤的其他候選藥物。
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:40 ET AI 時代下，企業私有雲也需要超進化：Dell Private Cloud 打造兼具彈性與效率的現代化架構
減少 90% 的佈建步驟，在短短 2.5 小時內完成一個工作負載就緒的叢集部署，全程無需人工介入；實現零接觸安全上線（Zero-Touch Onboarding）、集中庫存管理與 Dell AIOps 整合；無論是 Kubernetes 叢集、資料庫服務，或 CI/CD 自動化部署需求，都能透過更一致的方式完成管理。加速 AI 從概念到生產DAP 現已擴展至 Dell AI Factory，透過安全框架部署經過驗證的優化解決方案，提供可重複執行的
More news about: Dell Technologies
May 30, 2026, 09:09 ET Il Gruppo Menarini presenta nuovi dati dello studio ELEVATE di fase 1b/2 su elacestrant in combinazione con capivasertib in pazienti con carcinoma mammario metastatico (mBC) ER+, HER2- in occasione del Congresso annuale 2026 dell'American Society of Clinical Oncology (ASCO)
negli Stati Uniti, in Europa e in altre regioni del mondo. Stemline commercializza anche tagraxofusp-erzs, una nuova terapia mirata diretta contro il CD123, per pazienti affetti da neoplasia a cellule dendritiche plasmacitoidi blastiche (BPDCN), un tumore ematologico aggressivo, negli Stati Uniti, in Europa
More news about: Menarini Industrie Farmaceutiche Riunite